A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis

NCT04744207 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

94

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Sclerosis

Interventions

DRUG: GS-248
DRUG: Placebo

Sponsor

Gesynta Pharma AB

Collaborators

[object Object]